China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.63
21.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 26.21 CNY with a low forecast of 25.25 CNY and a high forecast of 27.72 CNY.
Revenue
Forecast
Revenue Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 4%.
Operating Income
Forecast
Operating Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 8%. The projected CAGR for the next 2 years is 17%.
Net Income
Forecast
Net Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 8%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is China Resources Double-Crane Pharmaceutical Co Ltd's stock price target?
Price Target
26.21
CNY
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 26.21 CNY with a low forecast of 25.25 CNY and a high forecast of 27.72 CNY.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
4%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 4%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
17%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 8%. The projected CAGR for the next 2 years is 17%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
8%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 8%.
